Published Date: 07 Aug 2025
Machine learning uncovers gut microbiome biomarkers linked to purine metabolism, enhancing diagnostic strategies for gout and hyperuricemia.
Read Full NewsExtended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.
Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.
1.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
2.
a brand-new generic therapy for different types of cancer.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
5.
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types
1.
Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology
2.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
3.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
4.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation